Pacira Biosciences, Inc.

Is Pacira Biosciences, Inc. technically bullish or bearish?

As of October 24, 2025, Pacira Biosciences, Inc. shows a neutral trend with mixed technical signals, underperforming the S&P 500 recently but outperforming it year-to-date and over the past year, suggesting a cautious investment approach.

As of 24 October 2025, the technical trend for Pacira Biosciences, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across various indicators. The MACD shows a bearish signal on the weekly chart but is mildly bullish on the monthly chart. The Bollinger Bands and moving averages indicate bearish and mildly bullish trends, respectively. The KST is bullish weekly and mildly bullish monthly, while Dow Theory and OBV are both mildly bearish on a weekly and monthly basis.<BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -4.94% and -16.55% compared to 1.92% and 2.32% for the index. However, it has outperformed the S&P 500 on a year-to-date and one-year basis, with returns of 15.39% and 27.73% versus 15.47% and 16.90%, respectively. Overall, the mixed signals suggest a cautious approach.

Is Pacira Biosciences, Inc. overvalued or undervalued?

As of November 6, 2024, Pacira Biosciences, Inc. is considered risky due to its overvaluation metrics compared to peers, despite a strong year-to-date stock performance, but it has significantly underperformed over the long term.

As of 6 November 2024, the valuation grade for Pacira Biosciences, Inc. has moved from attractive to risky, indicating a significant shift in its perceived value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 19, a Price to Book Value of 1.51, and an EV to EBITDA of 7.56. In comparison, peers such as PTC Therapeutics, Inc. have a P/E of 5.85 and an EV to EBITDA of 3.17, while Supernus Pharmaceuticals, Inc. is considered expensive with a P/E of 37.12 and an EV to EBITDA of 13.83.<BR><BR>Recent stock performance shows that while Pacira has outperformed the S&P 500 year-to-date with a return of 41.45% compared to 12.22%, it has significantly lagged over the longer term, particularly in the 3-year and 5-year periods with returns of -50.28% and -56.15%, respectively. This long-term underperformance, coupled with its risky valuation grade, suggests that investors should approach Pacira with caution.

How big is Pacira Biosciences, Inc.?

As of Jun 18, Pacira Biosciences, Inc. has a market capitalization of 1,129.37 million, with net sales of 702.76 million and a net profit of -103.73 million over the latest four quarters. Shareholder's funds are at 778.35 million, and total assets amount to 1,553.52 million.

As of Jun 18, Pacira Biosciences, Inc. has a market capitalization of 1,129.37 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company's net sales for the latest four quarters totaled 702.76 million, while the net profit for the same period was -103.73 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 778.35 million and total assets amounting to 1,553.52 million.

What does Pacira Biosciences, Inc. do?

Pacira Biosciences, Inc. is a pharmaceutical company specializing in the development and commercialization of products using its DepoFoam extended release technology. As of March 2025, it reported net sales of $169 million and a market cap of approximately $1.13 billion.

Overview:<BR>Pacira Biosciences, Inc. is a pharmaceutical company focused on the development, manufacture, and commercialization of pharmaceutical products utilizing its DepoFoam extended release drug delivery technology, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 169 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 5 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,129.37 Million (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: 19.00 <BR>Debt Equity: 0.12 <BR>Return on Equity: 7.73% <BR>Price to Book: 1.41 <BR><BR>Contact Details:<BR>Address: 5 Sylvan Way Ste 300, PARSIPPANY NJ: 07054-3813 <BR>Tel: ['1 973 2543560', '1 973 4514030'] <BR>Fax: 1 302 6555049 <BR>Website: http://www.pacira.com/

Should I buy, sell or hold Pacira Biosciences, Inc.?

Who are in the management team of Pacira Biosciences, Inc.?

As of March 2022, the management team of Pacira Biosciences, Inc. includes David Stack as Chairman and CEO, Paul Hastings as Lead Independent Director, and independent directors Christopher Christie, Laura Brege, Mark Froimson, and Yvonne Greenstreet.

As of March 2022, the management team of Pacira Biosciences, Inc. includes Mr. David Stack, who serves as the Chairman of the Board and Chief Executive Officer. Other key members are Mr. Paul Hastings, the Lead Independent Director, and several independent directors: Gov. Christopher Christie, Ms. Laura Brege, Dr. Mark Froimson, and Dr. Yvonne Greenstreet.